Candesartan cilexetil tablets

Candesartan cilexetil is rapidly hydrolyzed into active metabolites in the body, candesartan, which is a selective angiotensin II receptor (AT1) antagonist. It antagonizes the vasoconstriction of angiotensin II by binding to the AT1 receptor of vascular smooth muscle, thereby reducing peripheral vascular resistance. It is also believed that candesartan can exert a certain antihypertensive effect by inhibiting the secretion of aldosterone by the adrenal gland. Candesartan does not inhibit kininase II and does not affect the degradation of bradykinin. Experiments conducted on hypertensive patients showed that repeated use of this product can increase plasma renin activity, angiotensin 1 concentration, and angiotensin II concentration; continuous use of this product 2-8 mg once a day can reduce systolic and diastolic blood pressure, left ventricular myocardial weight, and peripheral vascular resistance, but has no significant effect on cardiac output, ejection fraction, renal vascular resistance, renal blood flow, and glomerular filtration rate; it has no effect on cerebral blood flow in patients with primary hypertension with cerebrovascular disorders.

The main ingredient of this product is candesartan cilexetil. Chemical name: (±)-1-(cyclohexyloxycarbonyloxy)ethyl-[2-ethoxy-1-[[2'-(1H-tetrazolyl-5)biphenyl-4]methyl]-1H-benzimidazole-7]carboxylate Molecular weight: C33H34N6O6

This product is white or off-white tablets.

Used to treat essential hypertension. This product can be used alone or in combination with other antihypertensive drugs.

Oral administration: Generally, adults take 4-8 mg of candesartan cilexetil once a day. The dose can be increased to 12 mg if necessary.

1. Serious adverse effects (incidence unknown): (1) Angioedema: Angioedema with edema symptoms of face, lips, tongue, pharynx, larynx, etc. may occur. Careful observation should be conducted. If abnormality is observed, the drug should be discontinued and appropriate treatment should be given. (2) Syncope and loss of consciousness: Excessive blood pressure reduction may cause syncope and temporary loss of consciousness. In this case, the drug should be discontinued and appropriate treatment should be given. In particular, patients undergoing hemodialysis, patients undergoing strict salt restriction therapy, and patients who have recently started taking diuretic antihypertensive drugs may experience a rapid drop in blood pressure. Therefore, these patients should start taking this drug at a lower dose. If it is necessary to increase the dose, the patient's condition should be closely observed and the dose should be increased slowly. (3) Acute renal failure: Acute renal failure may occur. The patient's condition should be closely observed. If abnormality is found, the drug should be discontinued and appropriate treatment should be given. (4) Patients with hyperkalemia: In view of the possibility of hyperkalemia, the patient's condition should be closely observed. If abnormality is found, the drug should be discontinued and appropriate treatment should be given. (5) Deterioration of liver function or jaundice: In view of the possibility of liver dysfunction or jaundice with elevated AST (GOT), ACT (GPTO, γ-GTP) values, the patient's condition should be closely observed. If abnormalities are found, the medication should be discontinued and appropriate treatment should be given. (6) Agranulocytosis: Agranulocytosis may occur and the patient's condition should be closely observed. If abnormalities are found, the medication should be discontinued and appropriate treatment should be given. (7) Rhabdomyolysis: Symptoms such as myalgia, weakness, increased CK, and myosin in the blood and urine may occur. If the above conditions occur, the medication should be discontinued and appropriate treatment should be given. (8) Interstitial pneumonia: Interstitial pneumonia accompanied by fever, cough, dyspnea, and abnormal chest X-ray examination may occur. If the above conditions occur, the medication should be discontinued and appropriate treatment should be given, such as treatment with corticosteroids.

1. Patients with a history of allergy to the ingredients of this preparation. 2. Women who are pregnant or may become pregnant. 3. Patients with severe liver or kidney dysfunction or cholestasis.

Precautions for children: The safety of the drug for children has not been determined (no experience). Precautions for pregnancy and lactation: Women who are pregnant or may become pregnant. Precautions for the elderly: It is generally believed that blood pressure should not be excessively lowered for the elderly (it may cause cerebral infarction, etc.). It should be used with caution while the patient is under observation.

Note that this product has no significant interactions with glyburide, nimodipine, digoxin, warfarin, hydrochlorothiazide and other drugs. There is also no significant interaction when healthy subjects take oral contraceptives.

Keep sealed.

4 mg

36 months

Fuzhou Pingshan Medicine Limited Company

• Founded in:

  2003-12-15

• Address:

  Room B, 13th Floor, Area A, Olympic Sports City Garden (Qinting Garden Plaza), No. 321, Wusi Road, Gulou District, Fuzhou City, Fujian Province

• Tax NO.:

  91350100757358223M

• Registered Funds:

  33 million yuan

• Email:

  Log in to view